Metabolic Reprogramming in Cholangiocarcinoma

Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

(2022) Mikel Ruiz de Gauna et al.   HEPATOLOGY

A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome

(2022) Courtney D. DiNardo et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma

(2021) Chiara Raggi et al.   JOURNAL OF HEPATOLOGY

High glucose upregulates FOXM1 expression via EGFR/STAT3 dependent activation to promote progression of cholangiocarcinoma

(2021) Marutpong Detarya et al.   LIFE SCIENCES

Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis

(2021) Kenji Ohshima et al.   Metabolites

Serotonin Pathway in Cancer

(2021) Pragathi Balakrishna et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

(2021) Analia Azaro et al.   INVESTIGATIONAL NEW DRUGS

Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells

(2021) Sabina Di Matteo et al.   Scientific Reports

Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models

(2021) Malinee Thanee et al.   Cancer & Metabolism

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

(2021) Ingo K. Mellinghoff et al.   CLINICAL CANCER RESEARCH

Long noncoding RNA FAM66C promotes tumor progression and glycolysis in intrahepatic cholangiocarcinoma by regulating hsa‐miR ‐23b‐3p/ KCND2 axis

(2021) Guang‐Lin Lei et al.   ENVIRONMENTAL TOXICOLOGY

CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5‐lipoxygenase

(2021) Yuli Lin et al.   HEPATOLOGY

Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma

(2021) Jae Pil Hwang et al.   MEDICINE

The implications of IDH mutations for cancer development and therapy

(2021) Christopher J. Pirozzi et al.   Nature Reviews Clinical Oncology

Targeting Fatty Acid Synthase Modulates Metabolic Pathways and Inhibits Cholangiocarcinoma Cell Progression

(2021) Jittima Tomacha et al.   Frontiers in Pharmacology

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

(2021) Andrew X. Zhu et al.   JAMA Oncology

Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma

(2021) Sureerat Padthaisong et al.   Cancer & Metabolism

Tumor Lymphatic Interactions Induce CXCR2-CXCL5 Axis and Alter Cellular Metabolism and Lymphangiogenic Pathways to Promote Cholangiocarcinoma

(2021) Sukanya Roy et al.   Cells

ROS in cancer therapy: the bright side of the moon

(2020) Bruno Perillo et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

(2020) Zenon Konteatis et al.   ACS Medicinal Chemistry Letters

Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives

(2020) Mirella Pastore et al.   Cells

Role of the mTOR pathway in liver cancer: from molecular genetics to targeted therapies

(2020) Xinjun Lu et al.   HEPATOLOGY

CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling

(2020) Lixia Gao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma

(2020) Sara Massironi et al.   Cells

Improving the Treatment of Acute Lymphoblastic Leukemia

(2020) Ashish Radadiya et al.   BIOCHEMISTRY

Cancer Cells Don’t Live Alone: Metabolic Communication within Tumor Microenvironments

(2020) Fuming Li et al.   DEVELOPMENTAL CELL

NRF2, a Transcription Factor for Stress Response and Beyond

(2020) Feng He et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

(2020) Jesus M. Banales et al.   Nature Reviews Gastroenterology & Hepatology

JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma

(2020) Elisa Manieri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

KDM5C Represses FASN-Mediated Lipid Metabolism to Exert Tumor Suppressor Activity in Intrahepatic Cholangiocarcinoma

(2020) Bo Zhang et al.   Frontiers in Oncology

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives

(2020) Fabiana Crispo et al.   MOLECULES

Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes

(2020) Chin-Hsiao Tseng   Frontiers in Oncology

High glucose‐ROS conditions enhance the progression in cholangiocarcinoma via upregulation of MAN2A2 and CHD8

(2020) Unchalee Thonsri et al.   CANCER SCIENCE

Serine, glycine and one‑carbon metabolism in cancer (Review)

(2020) Sijing Pan et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells

(2020) Charupong Saengboonmee et al.   LIFE SCIENCES

BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma

(2020) Keiichi Tamai et al.   Scientific Reports

Nuclear Magnetic Resonance-Based Metabolomic Analysis of the Anticancer Effect of Metformin Treatment on Cholangiocarcinoma Cells

(2020) Jin Zhang et al.   Frontiers in Oncology

Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis

(2019) Mingming Zhang et al.   Cell Communication and Signaling

Molecular Pathogenesis of Cholangiocarcinoma

(2019) Peter L. Labib et al.   BMC CANCER

Dual Role of Bile Acids on the Biliary Epithelium: Friend or Foe?

(2019) Leonardo Baiocchi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

(2019) Bin Fan et al.   INVESTIGATIONAL NEW DRUGS

SIRT3 elicited an anti‐Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis

(2019) Lei Xu et al.   Cancer Medicine

The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming

(2019) Lei Xu et al.   NEOPLASIA

Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer

(2019) Neha M. Akella et al.   BMC BIOLOGY

Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis

(2019) Jingxiao Wang et al.   JOURNAL OF HEPATOLOGY

PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma

(2019) Ze Qian et al.   Clinics and Research in Hepatology and Gastroenterology

Low VDAC1 Expression Is Associated with an Aggressive Phenotype and Reduced Overall Patient Survival in Cholangiocellular Carcinoma

(2019) René Günther Feichtinger et al.   Cells

UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals

(2019) Jianhua Yu et al.   BIOCHEMICAL PHARMACOLOGY

Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location

(2019) Risa Nakagawa et al.   Medical Molecular Morphology

Methionine adenosyltransferases in liver cancer

(2019) Ben Murray et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Metabolic rearrangements in primary liver cancers: cause and consequences

(2019) Letizia Satriano et al.   Nature Reviews Gastroenterology & Hepatology

Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma

(2019) Zai-Fa Hong et al.   BIOMEDICINE & PHARMACOTHERAPY

Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer

(2019) Marteinn Thor Snaebjornsson et al.   Cell Metabolism

Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation

(2019) Hiroaki Fujiwara et al.   Scientific Reports

Glutamine deprivation counteracts hypoxia-induced chemoresistance

(2019) Jessica Wappler et al.   NEOPLASIA

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

(2018) O. Erice et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

(2018) David K. Lau et al.   BRITISH JOURNAL OF CANCER

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas

(2018) Julia Delahousse et al.   EUROPEAN JOURNAL OF CANCER

Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer

(2018) Ting Liu et al.   GASTROENTEROLOGY

Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis

(2018) Yoshinobu Ikeno et al.   Journal of Translational Medicine

O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1

(2018) Chatchai Phoomak et al.   ONCOGENE

PGC1α promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect

(2018) Dan Li et al.   Cell Death & Disease

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

(2018) C Massard et al.   ANNALS OF ONCOLOGY

Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis

(2018) Jesus M Banales et al.   HEPATOLOGY

The Roles of Autophagy in Cancer

(2018) Chul Yun et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

(2018) James J. Harding et al.   Cancer Discovery

Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells

(2017) Wei Fan et al.   HEPATOLOGY

Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4

(2017) Jihua Nie et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice

(2017) Shanshan Zhang et al.   JOURNAL OF HEPATOLOGY

Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages

(2017) Chiara Raggi et al.   JOURNAL OF HEPATOLOGY

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

(2017) Angela Alistar et al.   LANCET ONCOLOGY

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

(2017) Young Shin Cho et al.   ACS Medicinal Chemistry Letters

Reduced levels of N’-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival

(2017) Kyung-Hee Kim et al.   Oncotarget

Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1 -mutated or IDH2 -mutated solid tumours

(2017) Remco J Molenaar et al.   BMJ Open

Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS

(2017) Xianzhi Qu et al.   PLoS One

High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation

(2017) Chatchai Phoomak et al.   Scientific Reports

CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment

(2016) Malinee Thanee et al.   CANCER SCIENCE

Metabolic Heterogeneity in Human Lung Tumors

(2016) Christopher T. Hensley et al.   CELL

Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma

(2016) Lei Jiang et al.   CLINICAL NUCLEAR MEDICINE

FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling

(2016) Li Guan et al.   HEPATOLOGY

Differential requirement forde novolipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans

(2016) Lei Li et al.   HEPATOLOGY

Deregulated methionine adenosyltransferase α1, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans‡

(2016) Heping Yang et al.   HEPATOLOGY

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition

(2016) Marco Sciacovelli et al.   NATURE

Cancer metabolism: a therapeutic perspective

(2016) Ubaldo E. Martinez-Outschoorn et al.   Nature Reviews Clinical Oncology

Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents

(2016) Papavee Samatiwat et al.   TUMOR BIOLOGY

Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice

(2016) Ning Ding   WORLD JOURNAL OF GASTROENTEROLOGY

Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer

(2016) Gianmaria Miolo et al.   Oncotarget

Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells

(2016) Xiwei Ding et al.   Oncotarget

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy

(2016) Luca Faloppi et al.   Scientific Reports

Fundamentals of cancer metabolism

(2016) R. J. DeBerardinis et al.   Science Advances

High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation

(2016) Charupong Saengboonmee et al.   Scientific Reports

Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-κB

(2016) Chatchai Phoomak et al.   Scientific Reports

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

(2015) Zhaoyong Li et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Cellular and molecular effects of the mTOR inhibitor everolimus

(2015) U. Saran et al.   CLINICAL SCIENCE

Relationship between 18-F-fluoro-deoxy-d-glucose uptake and expression of glucose transporter 1 and pyruvate kinase M2 in intrahepatic cholangiocarcinoma

(2015) Hideki Suzuki et al.   DIGESTIVE AND LIVER DISEASE

Metformin does not improve survival of cholangiocarcinoma patients with diabetes

(2015) Zhen Yang et al.   HEPATOLOGY

Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach

(2015) Lian Chen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

(2015) Guanzhen Yu et al.   Molecular Cancer

Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma

(2015) Xingming Jiang et al.   Oncotarget

Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma

(2015) Yoshiki Murakami et al.   Scientific Reports

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study

(2014) R. Buzzoni et al.   ANNALS OF ONCOLOGY

Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy

(2014) Hyun Jung Kee et al.   BMB Reports

Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration

(2014) Keatdamrong Janpipatkul et al.   CELLULAR SIGNALLING

Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2

(2014) Runping Liu et al.   HEPATOLOGY

Epigenetic reprogramming modulates malignant properties of human liver cancer

(2014) Chiara Raggi et al.   HEPATOLOGY

Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma

(2014) Yuichiro Kubo et al.   HUMAN PATHOLOGY

Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines

(2014) SUNBIN LING et al.   ONCOLOGY REPORTS

Expression and roles of fatty acid synthase in hepatocellular carcinoma

(2014) QIWEI HAO et al.   ONCOLOGY REPORTS

Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment

(2014) Yaping Yu et al.   World Journal of Surgical Oncology

Microenvironment and tumor cell plasticity: An easy way out

(2013) Maria Letizia Taddei et al.   CANCER LETTERS

Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development

(2013) Elisa Lozano et al.   MOLECULAR CANCER RESEARCH

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Sphingosine 1-phosphate signalling in cancer

(2012) Nigel J. Pyne et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer

(2012) Dipok Kumar Dhar et al.   CANCER

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c

(2012) Asami Hagiwara et al.   Cell Metabolism

Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk

(2012) Roongruedee Chaiteerakij et al.   HEPATOLOGY

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

(2012) Benjamin R. Kipp et al.   HUMAN PATHOLOGY

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

(2012) P Wang et al.   ONCOGENE

DNA Methylation Suppresses Expression of the Urea Cycle Enzyme Carbamoyl Phosphate Synthetase 1 (CPS1) in Human Hepatocellular Carcinoma

(2011) Hongyan Liu et al.   AMERICAN JOURNAL OF PATHOLOGY

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes

(2011) Elaine Studer et al.   HEPATOLOGY

Risk factors for cholangiocarcinoma

(2011) Gia L. Tyson et al.   HEPATOLOGY

Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer

(2010) R. A. Igal   CARCINOGENESIS

High-Mannose Glycans are Elevated during Breast Cancer Progression

(2010) Maria Lorna A. de Leoz et al.   MOLECULAR & CELLULAR PROTEOMICS

The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma

(2009) J.-Y. Chung et al.   CLINICAL CANCER RESEARCH

Regulation of Bile Acid and Cholesterol Metabolism by PPARs

(2009) Tiangang Li et al.   PPAR Research

Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth

(2008) G. Alpini et al.   CANCER RESEARCH